Author:
Hu Haoyue,Tan Songtao,Xie Meng,Guo Peng,Yu Qiang,Xiao Juan,Zhao Kangrui,Liao Qiong,Wang Yi
Abstract
In non-small cell lung cancer (NSCLC), two key genetic alterations, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, are commonly believed to be mutually exclusive. Studies have reported that concurrent EGFR/ALK co-mutation in non-small cell lung cancer patients is rare, with a prevalence ranging from 0.1% to 1.6%. However, the clinical and pathological characteristics of these patients are not well-defined, and the optimal treatment approach for such cases remains controversial. In this report, we present a case of stage IV lung adenocarcinoma with both epidermal growth factor receptor and anaplastic lymphoma kinase mutations, along with high PD-L1 expression. The patient initially received treatment with epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), but the disease progressed. However, following a switch to ALK-TKI therapy and local radiotherapy, the lesion showed regression. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for non-small cell lung cancer patients with concurrent epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
Subject
Pharmacology (medical),Pharmacology
Reference34 articles.
1. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts);Barlesi;J. Clin. Oncol.,2013
2. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene;Chen;Lung cancer (Amsterdam, Neth).,2013
3. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene;Chiari;J. Clin. Oncol. official J. Am. Soc. Clin. Oncol.,2014
4. Successful management of lung adenocarcinoma with ALK/EGFR coalterations and PD-L1 overexpression by bevacizumab combined with chemotherapy;He;Angiogenesis,2022
5. EML4-ALK: honing in on a new target in non-small cell lung cancer;Horn;J. Clin. Oncol. official J. Am. Soc. Clin. Oncol.,2009